RAPT Therapeutics (RAPT) News Today → Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad) Free RAPT Stock Alerts $8.10 +0.30 (+3.85%) (As of 04/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineHold Rating on RAPT Therapeutics Amid Promising Data and Regulatory Uncertaintiesmarkets.businessinsider.com - April 12 at 8:27 AMRAPT reports positive phase 2 cancer trial resultsinvesting.com - April 11 at 1:51 AMMaintaining Hold Rating on RAPT Therapeutics Amidst Mixed Clinical Results and Regulatory Uncertaintymarkets.businessinsider.com - April 10 at 8:50 PMRAPT Therapeutics (NASDAQ:RAPT) Earns Neutral Rating from HC Wainwrightmarketbeat.com - April 10 at 8:17 AMRAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patientsglobenewswire.com - April 9 at 12:00 PM3 Biotech Stocks to Dump Before They Go to Zeroinvestorplace.com - April 9 at 6:31 AMRAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Consensus Recommendation of "Moderate Buy" from Analystsmarketbeat.com - April 4 at 2:31 AMShort Interest in RAPT Therapeutics, Inc. (NASDAQ:RAPT) Rises By 32.5%marketbeat.com - April 1 at 8:31 AMRAPT Therapeutics (NASDAQ:RAPT) Price Target Cut to $13.00marketbeat.com - March 27 at 10:59 AMRAPT Apr 2024 10.000 putfinance.yahoo.com - March 16 at 8:39 AMSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of RAPT Therapeutics, Inc. - RAPTprnewswire.com - March 11 at 6:06 PMHold Rating on RAPT Therapeutics Amid Clinical Trial Uncertainties and Financial Concernsmarkets.businessinsider.com - March 11 at 8:04 AMRAPT Oct 2024 5.000 callfinance.yahoo.com - March 8 at 12:09 AMRAPT Stock Earnings: RAPT Therapeutics Beats EPS for Q4 2023investorplace.com - March 7 at 5:03 PMRAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Resultsglobenewswire.com - March 7 at 8:00 AMRAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meetingglobenewswire.com - March 5 at 4:30 PMSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of RAPT Therapeutics, Inc. - RAPTprnewswire.com - March 3 at 10:15 AMRAPT Therapeutics, Inc. (NASDAQ:RAPT) Shares Bought by Braidwell LPmarketbeat.com - March 1 at 10:18 AMFmr LLC Grows Holdings in RAPT Therapeutics, Inc. (NASDAQ:RAPT)marketbeat.com - February 29 at 5:29 AMRAPT Therapeutics, Inc. (RAPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoingsbusinesswire.com - February 26 at 4:00 AMRAPT May 2024 17.500 putfinance.yahoo.com - February 23 at 6:30 AMUBS Downgrades RAPT Therapeutics (RAPT)msn.com - February 22 at 10:53 PMRAPT Therapeutics (NASDAQ:RAPT) Downgraded by UBS Group to Neutralmarketbeat.com - February 22 at 7:20 AMHC Wainwright & Co. Downgrades RAPT Therapeutics (RAPT)msn.com - February 21 at 9:05 PMLeerink Partners Downgrades RAPT Therapeutics (RAPT)msn.com - February 21 at 9:05 PMRapt Therapeutics just downgraded at Leerink, here's whyrealmoney.thestreet.com - February 21 at 4:04 PMJ.P. Morgan cuts RAPT to neutral, recommends against buying dipmsn.com - February 21 at 4:04 PMH.C. Wainwright cuts RAPT to neutral, cites delays due to clinical holdmsn.com - February 21 at 4:04 PMWhat's Going On With RAPT Therapeutics Stock On Wednesday?markets.businessinsider.com - February 21 at 4:04 PMBarclays Lowers RAPT Therapeutics (NASDAQ:RAPT) Price Target to $13.00marketbeat.com - February 21 at 11:19 AMInsider Buyers Lose Additional US$63k As RAPT Therapeutics Dips To US$236mfinance.yahoo.com - February 21 at 10:24 AMRAPT Therapeutics (NASDAQ:RAPT) Rating Lowered to Market Perform at SVB Leerinkmarketbeat.com - February 21 at 7:31 AMRapt Therapeutics just downgraded at JPMorgan, here's whyrealmoney.thestreet.com - February 21 at 12:05 AMRAPT Therapeutics (NASDAQ:RAPT) Crashes 60% after FDA Places Clinical Holdmsn.com - February 21 at 12:05 AMRapt Therapeutics just downgraded at Cantor Fitzgerald, here's whyrealmoney.thestreet.com - February 20 at 7:05 PMPeninsula biotech halts 2 clinical trials, stock loses 70% of valuebizjournals.com - February 20 at 7:05 PMRapt Therapeutics Crashes 74% After Unexpected Liver Failure Sidelines Two Testsfinance.yahoo.com - February 20 at 7:05 PMFDA Puts Hold On RAPT's Phase 2 Trials For Zelnecirnon In Atopic Dermatitis, Asthma; Stock Tanks 65%markets.businessinsider.com - February 20 at 2:05 PMRapt Therapeutics Crashes 65% After Unexpected Liver Failure Sidelines Two Testsmsn.com - February 20 at 2:05 PMRAPT Therapeutics Stock Is Down 64%. FDA Halts 2 Studies After Liver Failure.msn.com - February 20 at 2:05 PMRAPT Therapeutics Stock Is Down 63%. FDA Halts 2 Studies After Liver Failure.finance.yahoo.com - February 20 at 2:05 PMRapt Therapeutics Crashes 72% After Unexpected Liver Failure Sidelines Two Testsfinance.yahoo.com - February 20 at 2:05 PMRapt Therapeutics Crashes 65% After Unexpected Liver Failure Sidelines Two Testsinvestors.com - February 20 at 12:14 PMRAPT Therapeutics (NASDAQ:RAPT) Downgraded by Cantor Fitzgerald to "Neutral"marketbeat.com - February 20 at 11:23 AMRAPT Therapeutics, Inc.: RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnonfinanznachrichten.de - February 20 at 9:04 AMRAPT Therapeutics says FDA puts two mid-stage trials of company's drug on holdca.news.yahoo.com - February 20 at 9:04 AMTwo RAPT Therapeutics Studies Put on Hold by FDA After Adverse Eventmarketwatch.com - February 20 at 9:04 AMFDA puts on hold two drug trials of Rapt Therapeutics in 'major setback'reuters.com - February 20 at 9:04 AMRAPT Therapeutics’ stock plunges as FDA halts two clinical trialsmsn.com - February 20 at 9:04 AMRAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnonfinance.yahoo.com - February 20 at 9:04 AM Get RAPT Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RAPT and its competitors with MarketBeat's FREE daily newsletter. Email Address Protect Yourself While There’s Still Time … (Ad)The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom. 4 simple steps to protect your privacy and money before it’s too late. RAPT Media Mentions By Week RAPT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RAPT News Sentiment▼0.000.32▲Average Medical News Sentiment RAPT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RAPT Articles This Week▼02▲RAPT Articles Average Week Get RAPT Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RAPT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Enanta Pharmaceuticals News Today Werewolf Therapeutics News Today Vanda Pharmaceuticals News Today ESSA Pharma News Today Nanobiotix News Today Inozyme Pharma News Today Akebia Therapeutics News Today Renovaro News Today Verrica Pharmaceuticals News Today Erasca News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RAPT) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersFed launches fourth dollar overhaulStansberry ResearchJeff Bezos Just Humiliated Elon MuskInvestorPlaceBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RAPT Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
